Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.69 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | KCNA2 | P16389 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383938 | 0.86 | CYP3A4 (0.74) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Isopimpinellin SCHEMBL498907 | 0.82 | CYP3A4 (1.00) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Isopimpinellin SCHEMBL29568822 | 0.82 | CYP3A4 (1.00) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL29740208 | 0.81 | CYP1B1 (0.69) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL16352046 | 0.81 | CYP1B1 (0.69) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL6361059 | 0.78 | CYP3A4 (0.75) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL30985284 | 0.78 | KDM4E (0.71) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Pimpinellin SCHEMBL2255899 | 0.78 | CYP3A4 (1.00) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Pimpinellin SCHEMBL29162721 | 0.77 | CYP3A4 (0.97) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL5960652 | 0.75 | CYP3A4 (0.74) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | CYP3A4 544/4885KDM4E 3035/4885CYP1A2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.